Trachoma: Progress and Promise
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645


Trachoma is the world’s leading cause of preventable blindness. It affects approximately 150 million people living in the world’s poorest, rural communities and causes an estimated loss of $2.9 billion in productivity annually. In 1985, the Edna McConnell Clark Foundation joined with the World Health Organization to support studies on trachoma epidemiology and control, resulting in the elaboration of the surgery, antibiotics, facial cleanliness and environmental improvement (SAFE) strategy as the basis for the elimination of this blinding disease. Founded in 1998 by the Clark Foundation and Pfizer, Inc., the International Trachoma Initiative (ITI) is the only organization dedicated to eliminating blinding trachoma through support to national control programs. The availability of donated Zithromax (azithromycin) by Pfizer, Inc. has been paramount to the support of the ITI for implementation of SAFE in 10 country programs. The program has made considerable progress in four years. More than seven million individuals have received treatment, resulting in a cumulative reduction of 50% in active disease rates in children. More than 60,000 have also benefited from lid surgery that has halted progression to blindness. Morocco is expecting to attain the elimination of blinding trachoma by 2005. However, the challenges facing the goal of global elimination by 2020 involve a vital program expansion, increased financial and technical support, environmental improvement, and continued advocacy efforts.


Article metrics loading...

Loading full text...

Full text loading...



  1. Ezz al Arab G, Tawfik N, El Gendy R, Anwar W, Courtright P, 2001. The burden of trachoma in the rural Nile Delta of Egypt: a survey of Menofiya governorate. Br J Ophthalmol 85 : 1406–1410.
  2. Markel H, 2000. “The eyes have it”: trachoma, the perception of disease, the United States Public Health Service, and the American Jewish immigration experience, 1897–1924. Bull Hist Med 74 : 525–560.
  3. Allen S, Semba R, 2002. The trachoma “menace” in the United States 1867–1960. Surg Ophthamol 47 : 500–509.
  4. Marx R, 1989. Social factors and trachoma: a review of the literature. Soc Sci Med 29 : 23–34.
  5. Thylefors B, Negrel ADF, Pararajasegaram R, Dadzie KY, 1995. Global data on blindness. Bull World Health Organ. 73 : 115–121.
  6. Frick KD, Basilion EV, Hanson CL, Colchero MA, 2003. Estimating the burden and economic impact of trachomatous visual loss. Ophthalmic Epidemiol 10 : 121–132.
  7. Frick KD, Melia BM, Buhrmann RR, West SK, 2001. Trichiasis and disability in a trachoma-endemic area of Tanzania. Arch Ophthalmol 119 : 1839–1844.
  8. Thylefors B, 1996. Trachoma-new opportunities to tackle an old problem. Br J Ophthalmol 80 : 1033–1034.
  9. World Health Organization, 1952. Expert Committee on Trachoma: First Report. World Health Organ Tech Rep Ser 59.
  10. Ezz Al Arab G, Tawfik N, El Gendy R, Anwar W, Courtright P, 2001. The burden of trachoma in the rural Nile delta of Egypt: a survey of Menofiya governorate. Br J Ophthalmol 85 : 1406–1410.
  11. Walsh JA, Warren KS, 1980. Selective primary health care: an interim strategy for disease control in developing countries. Soc Sci Med 14 : 145–163.
  12. Reacher MH, Munoz B, Alghassany A, Daar AS, Elbualy M, Taylor HR, 1992. A controlled trial of surgery for trachomatous trichiasis of the upper lid. Arch Ophthalmol 110 : 667–674.
  13. Schachter J, West SK, Mabey D, Dawson CR, Bobo L, Bailey R, Vitale S, Quinn TC, Sheta A, Sallam S, Mkocha H, Mabey D, Faal H, 1999. Azithromycin in control of trachoma. Lancet 351 : 630–635.
  14. West S, Munoz B, Lynch M, Kayongoya A, Chilangwa Z, Mmbaga BB, Taylor HR, 1995. Impact of face-washing on trachoma in Kongwa, Tanzania. Lancet 345 : 155–158.
  15. Emerson PM, Cairncross S, Bailey RL, Mabey DC, 2000. Review of the evidence base for the ‘F’ and ‘E’ components of the SAFE strategy for trachoma control. Trop Med Int Health 5 : 515–527.
  16. World Health Organization, 1996. Future Approaches to Trachoma Control: Report of a Global Scientific Meeting. Geneva: World Health Organization. WHO/PBL/96.56.
  17. World Health Organization, 1998. World Health Assembly Resolution WHA 51.11. Geneva: World Health Organization.
  18. World Health Organization, 2003. World Health Assembly Resolution WHA 56.26. Geneva: World Health Organization.
  19. Dawson C, Schachter J, 1999. Can blinding trachoma be eliminated worldwide (editorial)? Arch Ophthalmol 117 : 974.
  20. World Health Organization, 1996. Future Approaches to Trachoma Control. Report of a Global Scientific Meeting. Geneva: June 17–20, 1996. WHO/PBL/96.56.
  21. International Trachoma Initiative. www.trachoma.org. Accessed 1 July 2003.
  22. Tabbara KF, Abuel-Asrar A, al-Omar O, Choudhury AH, al-Faisal Z, 1996. Single-dose azithromycin in the treatment of trachoma. A randomized, controlled study. Ophthalmology 103 : 842–846.
  23. Lietman T, Porco T, Dawson C, Blower S, 1999. Global elimination of trachoma: how frequently should we administer mass chemotherapy? Nat Med 5 : 492–493.
  24. Guyatt H, 2003. The cost of delivering and sustaining a control programme for schistosomiasis and soil-transmitted helminthiasis. Acta Trop 86 : 267–274.
  25. Sharp D, 1998. Five countries targeted in new trachoma initiative. Lancet 352 : 1609.
  26. Thylefors B, Dawson CR, Jones BR, West SK, Taylor HR, 1987. A simple system for the assessment of trachoma and its complications. Bull World Helath Organ 65 : 477–483.
  27. World Health Organization, 1993. Primary Health Care Level Management of Trachoma. Geneva: World Health Organization. WHO/PBL/93.33.
  28. Kuper H, Solomon AW, Buchan J, Zondervan M, Foster A, Mabey D, 2003. A critical review of the SAFE strategy for the prevention of blinding trachoma. Lancet Infect Dis 3 : 372–381.
  29. Jha H, Chaudary JS, Bhatta R, Miao Y, Osaki-Holm S, Gaynor B, Zegans M, Bird M, Yi E, Holbrook K, Whitcher JP, Lietman T, 2002. Disappearance of trachoma from western Nepal. Clin Infect Dis 35 : 765–768.
  30. Basilion EV, Kilima PM, Turner VM, Mecaskey JW, 2002. Height as a proxy for weight in determining azithromycin treatment for paediatric trachoma. Trans R Soc Trop Med Hyg 96 : 691–694.
  31. Gaynor BD, Yi E, Lietman T, 2002. Rationale for mass antibiotic distribution for trachoma elimination. Int Ophthalmol Clin 42 : 85–92.
  32. Ashraf H, 2002. Tackle infectious disease to help the poor, says WHO. Lancet 359 : 499.

Data & Media loading...

  • Received : 30 Jul 2003
  • Accepted : 20 Sep 2003

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error